Literature DB >> 20009161

Autosomal dominant polycystic kidney disease and transplantation.

Mariusz Niemczyk1, Stanisław Niemczyk, Leszek Paczek.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder affecting 1 in 1,000 people and responsible for 10% of cases of the end stage renal disease (ESRD). Apart from renal manifestations, changes in other organs may be present. In the absence of contraindications, patients with ADPKD and ESRD should be referred to renal transplantation. The ADPKD patient may also need liver transplantation, or combined liver and kidney transplantation. Also, the patient with ADPKD may become a potential organ donor. The aim of our paper is to review the problems that the physicians deal with in ADPKD patients in pre- and post-transplant period.

Entities:  

Mesh:

Year:  2009        PMID: 20009161      PMCID: PMC2843931     

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  45 in total

Review 1.  Management of cerebral aneurysms in autosomal dominant polycystic kidney disease.

Authors:  Yves Pirson; Dominique Chauveau; Vicente Torres
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

Review 2.  Genetics and pathogenesis of polycystic kidney disease.

Authors:  Peter Igarashi; Stefan Somlo
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

3.  Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kimberly K McFann; Ann M Johnson
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

4.  Nephrolithiasis associated with autosomal dominant polycystic kidney disease: contemporary urological management.

Authors:  C S Ng; A Yost; S B Streem
Journal:  J Urol       Date:  2000-03       Impact factor: 7.450

5.  Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.

Authors:  R D Perrone; R Ruthazer; N C Terrin
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 6.  Pain management in polycystic kidney disease.

Authors:  Z H Bajwa; S Gupta; C A Warfield; T I Steinman
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

7.  Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.

Authors:  Danxia Zheng; Marieka Wolfe; Benjamin D Cowley; Darren P Wallace; Tamio Yamaguchi; Jared J Grantham
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

8.  Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Authors:  Robert Schrier; Kimberly McFann; Ann Johnson; Arlene Chapman; Charles Edelstein; Godela Brosnahan; Tevfik Ecder; Lyn Tison
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

9.  The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease.

Authors:  Franck A Belibi; Darren P Wallace; Tamio Yamaguchi; Marcy Christensen; Gail Reif; Jared J Grantham
Journal:  J Am Soc Nephrol       Date:  2002-11       Impact factor: 10.121

10.  Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease.

Authors:  Tomás Seeman; Jirí Dusek; Hana Vondrichová; Martin Kyncl; Ulrike John; Joachim Misselwitz; Jan Janda
Journal:  Blood Press Monit       Date:  2003-06       Impact factor: 1.444

View more
  4 in total

1.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

2.  Soy Protein Alleviates Hypertension and Fish Oil Improves Diastolic Heart Function in the Han:SPRD-Cy Rat Model of Cystic Kidney Disease.

Authors:  Naser H M Ibrahim; Sijo J Thandapilly; Yong Jia; Thomas Netticadan; Harold Aukema
Journal:  Lipids       Date:  2015-12-01       Impact factor: 1.880

3.  Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy.

Authors:  John Fredy Nieto-Ríos; Lina María Serna-Higuita; Sheila Alexandra Builes-Rodriguez; Ricardo Cesar Restrepo-Correa; Arbey Aristizabal-Alzate; Catalina Ocampo-Kohn; Angélica Serna-Campuzano; Natalia Cardona-Díaz; Nelson Darío Giraldo-Ramirez; Gustavo Adolfo Zuluaga-Valencia
Journal:  Colomb Med (Cali)       Date:  2016-03-30

4.  Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.

Authors:  Tao Xu; Nian-Song Wang; Li-Li Fu; Chao-Yang Ye; Sheng-Qiang Yu; Chang-Lin Mei
Journal:  Mol Biol Rep       Date:  2012-03-14       Impact factor: 2.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.